Cerity Partners LLC Makes New Investment in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA)

Key Points

• Cerity Partners LLC invested approximately $471,000 in Centessa Pharmaceuticals by acquiring 32,754 shares, adding to the company's substantial institutional ownership.
• Director Arjun Goyal significantly increased his stake in Centessa Pharmaceuticals by purchasing 417,646 shares for over $5.3 million, while another insider sold 15,000 shares.
• Analysts have a positive outlook on Centessa Pharmaceuticals, with several firms issuing buy ratings and target prices ranging from $30.00 to $38.00, reflecting strong growth potential.

Cerity Partners LLC purchased a new stake in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 32,754 shares of the company's stock, valued at approximately $471,000.

Several other institutional investors also recently bought and sold shares of CNTA. GF Fund Management CO. LTD. purchased a new stake in shares of Centessa Pharmaceuticals in the fourth quarter valued at approximately $31,000. Barclays PLC increased its position in shares of Centessa Pharmaceuticals by 1,414.9% during the fourth quarter. Barclays PLC now owns 5,302 shares of the company's stock worth $89,000 after purchasing an additional 4,952 shares in the last quarter. Bank of New York Mellon Corp purchased a new stake in shares of Centessa Pharmaceuticals during the first quarter worth approximately $147,000. BNP Paribas Financial Markets purchased a new stake in shares of Centessa Pharmaceuticals during the fourth quarter worth approximately $162,000. Finally, OMERS ADMINISTRATION Corp purchased a new stake in shares of Centessa Pharmaceuticals during the fourth quarter worth approximately $171,000. 82.01% of the stock is currently owned by hedge funds and other institutional investors.

Centessa Pharmaceuticals Trading Up 1.0%

Shares of CNTA stock traded up $0.15 on Tuesday, hitting $15.35. The stock had a trading volume of 31,232 shares, compared to its average volume of 925,220. The company has a debt-to-equity ratio of 0.28, a current ratio of 14.37 and a quick ratio of 14.37. The firm has a market capitalization of $2.05 billion, a P/E ratio of -8.37 and a beta of 1.45. Centessa Pharmaceuticals PLC Sponsored ADR has a 1 year low of $9.10 and a 1 year high of $19.09. The company's 50 day moving average price is $13.61 and its 200-day moving average price is $14.38.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.15. Analysts anticipate that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 earnings per share for the current year.

Insider Transactions at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, CEO Saurabh Saha sold 55,000 shares of the company's stock in a transaction dated Monday, July 21st. The stock was sold at an average price of $15.92, for a total transaction of $875,600.00. Following the sale, the chief executive officer owned 221,017 shares in the company, valued at $3,518,590.64. This represents a 19.93% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, General Counsel Iqbal J. Hussain sold 12,000 shares of the company's stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $14.02, for a total value of $168,240.00. Following the sale, the general counsel owned 105,386 shares in the company, valued at approximately $1,477,511.72. This trade represents a 10.22% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 222,311 shares of company stock worth $3,074,294. 7.09% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts recently commented on CNTA shares. Wall Street Zen upgraded Centessa Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. Chardan Capital began coverage on Centessa Pharmaceuticals in a research note on Thursday, May 8th. They set a "buy" rating and a $30.00 price objective on the stock. Truist Financial began coverage on Centessa Pharmaceuticals in a research note on Monday, July 21st. They set a "buy" rating and a $30.00 price objective on the stock. Oppenheimer began coverage on Centessa Pharmaceuticals in a research note on Thursday, May 8th. They set an "outperform" rating and a $6.00 price objective on the stock. Finally, Needham & Company LLC began coverage on Centessa Pharmaceuticals in a research note on Wednesday, May 28th. They set a "buy" rating and a $35.00 price objective on the stock. One analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat.com, Centessa Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $28.10.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.